dacomitinib podcasts

Dacomitinib, cemiplimab & #oncopharm updates

Play Episode Listen Later Oct 4, 2018 27:47

Dacomitinib & cemiplimab's respective FDA-approvals are discussed followed by a lightning-round review of 4 immunotherapy studies from the last week. We end with dosing updates for 2 multiple myeloma drugs.

fda dacomitinib

Is the Survival Benefit from Dacomitinib on the ARCHER-1050 Trial Enough to Make it a Contender as First Line Treatment for EGFR Mutation-Positive NSCLC Today? (BMIC-044)

The Beacon

Play Episode Listen Later Jul 5, 2018 7:05

Dr. Jack West reviews results from ARCHER-1050, a trial of dacomitinib vs. gefitinib, in EGFR mutation-positive NSCLC, asks whether the demonstrated survival benefit is enough to make dacomitinib a player as first line treatment.

positive trial treatments survival benefit contender mutation egfr nsclc jack west first line treatment dacomitinib

Dacomitinib: Dark Horse EGFR TKI Charges into a Crowded First Line Setting for EGFR Mutation-Positive Advanced NSCLC (BMIC-016)

The Beacon

Play Episode Listen Later Nov 28, 2017 7:54

Dr. Jack West reviews the results of the ARCHER-1050 trial that showed superior efficacy with dacomitinib vs. gefitinib in EGFR mutation-positive NSCLC. Is it too little, too late for dacomitinib, or can it find a place in a crowded first line setting?

positive horses charges dark horse mutation crowded first line egfr nsclc jack west advanced nsclc egfr tki dacomitinib

Dacomitinib for EGFR positive lung cancer

2017 ASCO Annual Meeting

Play Episode Listen Later Jul 28, 2017 6:51

Dr Mok presents results at an ASCO 2017 press briefing session from the ARCHER 1050 trial, a phase III trial of dacomitinib, a second-generation EGFR inhibitor, compared to gefitinib. He describes the increased efficacy of dacomitinib, boosting median PFS to 14.7 months compared to 9.2 months with gefitinib, but also that this stronger activity comes at the cost of more severe GI toxicities, requiring does modification.

positive gi lung cancer asco pfs egfr mok dacomitinib

Novel EGFR Inhibitors in the Setting of Acquired Resistance

GRACEcast

Play Episode Listen Later Nov 11, 2014 26:27

Acquired Resistance Forum Video #15: Dr. Pasi Jänne of Dana-Farber Cancer Institute spoke about EGFR inhibitors available to patients when Tarceva stops working for them.

cancer institute pasi inhibitors dana farber cancer institute egfr dana farber gracecast t790m cancergrace acquired resistance erlotinib tarceva iressa afatinib dacomitinib gefitinib azd9291 gilotrif co1686 acquired resistance forum video ap26113 t790

Novel EGFR Inhibitors in the Setting of Acquired Resistance

GRACEcast Lung Cancer Video

Play Episode Listen Later Nov 11, 2014 26:27

Acquired Resistance Forum Video #15: Dr. Pasi Jänne of Dana-Farber Cancer Institute spoke about EGFR inhibitors available to patients when Tarceva stops working for them.

cancer institute pasi inhibitors dana farber cancer institute egfr dana farber gracecast t790m cancergrace acquired resistance erlotinib tarceva iressa afatinib dacomitinib gefitinib azd9291 gilotrif co1686 acquired resistance forum video ap26113 t790

Novel EGFR Inhibitors in the Setting of Acquired Resistance

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Nov 11, 2014 26:27

Acquired Resistance Forum Video #15: Dr. Pasi Jänne of Dana-Farber Cancer Institute spoke about EGFR inhibitors available to patients when Tarceva stops working for them.

cancer institute pasi inhibitors dana farber cancer institute egfr dana farber gracecast t790m cancergrace acquired resistance erlotinib tarceva iressa afatinib dacomitinib gefitinib azd9291 gilotrif co1686 acquired resistance forum video ap26113 t790